{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:01:46Z","timestamp":1768485706585,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Gynecologic Oncology Group Statistical and Data Center","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}]},{"name":"NRG Oncology","award":["U10 CA180822"],"award-info":[{"award-number":["U10 CA180822"]}]},{"name":"NRG Operations","award":["U10CA180868"],"award-info":[{"award-number":["U10CA180868"]}]},{"name":"NRG Operations","award":["UG1CA189867"],"award-info":[{"award-number":["UG1CA189867"]}]},{"DOI":"10.13039\/100001006","name":"Breast Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001006","id-type":"DOI","asserted-by":"publisher"}]},{"name":"MSK Cancer Center","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.ygyno.2018.12.008","type":"journal-article","created":{"date-parts":[[2018,12,23]],"date-time":"2018-12-23T16:03:03Z","timestamp":1545580983000},"page":"548-553","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"152","author":[{"given":"Ursula A.","family":"Matulonis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael W.","family":"Sill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vicky","family":"Makker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-1581","authenticated-orcid":false,"given":"David G.","family":"Mutch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jay W.","family":"Carlson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher J.","family":"Darus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert S.","family":"Mannel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David P.","family":"Bender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin K.","family":"Crane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carol","family":"Aghajanian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2018.12.008_bb0005","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegal","year":"2018","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.ygyno.2018.12.008_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199601043340101","article-title":"Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer","volume":"334","author":"McGuire","year":"1996","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.ygyno.2018.12.008_bb0015","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","article-title":"Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup","volume":"27","author":"Bookman","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2018.12.008_bb0020","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0025","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(17)30279-6","article-title":"Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology\/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial","volume":"18","author":"Coleman","year":"2017","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2018.12.008_bb0030","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0035","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","article-title":"Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth","volume":"10","author":"Yakes","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/nrc3205","article-title":"Targeting MET in cancer: rationale and progress","volume":"12","author":"Gherardi","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1593\/neo.09948","article-title":"An orally available small molecule inhibitor of c-Met, PF-2341066, reduces tumor burden and metastasis in a preclinical model of ovarian cancer metastasis","volume":"12","author":"Zillhardt","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ejca.2017.06.018","article-title":"A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma","volume":"83","author":"Vergote","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0055","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","article-title":"Phase II randomized discontinuation trial of cabozantinib in patients with solid tumors","volume":"86","author":"Schoffski","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0060","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S1470-2045(16)30107-3","article-title":"Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open label phase 3 trial","volume":"17","author":"Choueiri","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0065","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1200\/JCO.2016.70.7398","article-title":"Cabozantinib versus sunitinib as initial targeted therapy for patients with metastatic renal cell carcinoma of poor or intermediate risk: the Alliance A031203 CABOSUN trial","volume":"35","author":"Choueiri","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0070","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1177\/1758834017724314","article-title":"Cabozantinib in metastatic renal cell carcinoma: latest findings and clinical potential","volume":"9","author":"Bersanelli","year":"2017","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0075","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0080","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ejca.2017.09.011","article-title":"Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumors","volume":"86","author":"Schoffski","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0085","doi-asserted-by":"crossref","first-page":"5019","DOI":"10.1200\/JCO.2007.11.8711","article-title":"Randomized clinical trial design for assessing noninferiority when superiority is expected","volume":"25","author":"Freidlin","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0090","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0095","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"25","author":"Burger","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0100","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0105","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A phase II open labeled, study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0110","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejca.2012.07.020","article-title":"ENMD-2076, an oral inhibitor of angiogenic and proliferation kinases, has activity in recurrent, platinum resistant ovarian cancer","volume":"49","author":"Matulonis","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0115","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2012.07.126","article-title":"A phase II trial of sunitinib malate in recurrent and refractory ovarian, fallopian tube, and peritoneal cancer","volume":"128","author":"Campos","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0120","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S1470-2045(15)70115-4","article-title":"Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum resistant-refractory advanced ovarian cancer (MITO 11): a randomized, open-label, phase 2 trial","volume":"16","author":"Pignata","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0125","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1001\/jamaoncol.2017.4218","article-title":"Paclitaxel with and without pazopanib for persistent or recurrent ovarian cancer","volume":"4","author":"Richardson","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0130","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","article-title":"Phase II weekly paclitaxel (80\u202fmg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study","volume":"101","author":"Markman","year":"2006","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2018.12.008_bb0135","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1136\/ijgc-00009577-200303000-00007","article-title":"Weekly paclitaxel in patients with recurrent or persistent ovarian cancer","volume":"13","author":"Ghamande","year":"2003","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2018.12.008_bb0140","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ygyno.2003.12.002","article-title":"The effect of single agent weekly paclitaxel in heavily pretreated patients with recurrent or persistent advanced ovarian cancer","volume":"92","author":"Kita","year":"2004","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2018.12.008_bb0145","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ygyno.2018.04.572","article-title":"Phase II study of single-agent cabozantinib in patients with recurrent clear cell ovarian, primary peritoneal or fallopian tube cancer (NRG-GY001)","volume":"150","author":"Konstantinopoulos","year":"2018","journal-title":"Gynecol. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818314604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825818314604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:40:00Z","timestamp":1758771600000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825818314604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0090825818314604"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.12.008","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized phase II study of cabozantinib versus weekly paclitaxel in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2018.12.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}